Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
80.76
+2.53 (3.23%)
Jun 11, 2026, 10:58 AM EDT - Market open
Kymera Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 144.09 | 357.01 | 120.26 | 109.97 | 68.4 | 47.98 |
Short-Term Investments | 506.84 | 491.27 | 368.49 | 264.92 | 338.77 | 394.44 |
Cash & Short-Term Investments | 650.93 | 848.28 | 488.74 | 374.88 | 407.17 | 442.42 |
Cash Growth | 40.54% | 73.56% | 30.37% | -7.93% | -7.97% | 49.36% |
Accounts Receivable | - | - | - | 15 | - | - |
Other Receivables | - | - | - | 3.76 | 2.54 | 0.14 |
Total Trade Receivables | - | - | - | 18.76 | 2.54 | 0.14 |
Other Current Assets | 26.5 | 22.94 | 21.52 | 11.67 | 9.71 | 8.72 |
Total Current Assets | 677.43 | 871.21 | 510.27 | 405.32 | 419.42 | 451.27 |
Net Property, Plant & Equipment | 83.35 | 85.53 | 97.86 | 101.08 | 22.24 | 21.31 |
Long-Term Investments | 894.72 | 771.16 | 362.16 | 61.43 | 152.33 | 125.19 |
Other Long-Term Assets | 13.51 | 14.91 | 7.74 | 7.93 | 9.15 | 8.14 |
Total Assets | 1,669 | 1,743 | 978.04 | 575.76 | 603.13 | 605.91 |
Accounts Payable | 12.84 | 4.02 | 5.99 | 7.08 | 4.34 | 4.01 |
Accrued Expenses | 35.1 | 42.27 | 34.87 | 33.86 | 27.5 | 22.97 |
Current Portion of Leases | 13.73 | 13.76 | 13.11 | 6.35 | 3.94 | 3.6 |
Unearned Revenue | - | 22.93 | 13.58 | 37.88 | 35.26 | 61.74 |
Other Current Liabilities | 0.98 | 0.24 | 0.22 | 0.52 | 0.3 | 0.23 |
Total Current Liabilities | 62.64 | 83.21 | 67.77 | 85.69 | 71.34 | 92.54 |
Long-Term Leases | 66.74 | 68.5 | 74.65 | 78.33 | 13.39 | 14.36 |
Other Long-Term Liabilities | - | 11.44 | - | 16.77 | 28.25 | 39.36 |
Total Long-Term Liabilities | 66.74 | 79.94 | 74.65 | 95.1 | 41.64 | 53.73 |
Total Liabilities | 129.38 | 163.15 | 142.42 | 180.79 | 112.98 | 146.27 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 2,679 | 2,644 | 1,592 | 926.27 | 878.88 | 689.28 |
Accumulated Other Comprehensive Income | -4.19 | 1.8 | -1.49 | -0.55 | -4.95 | -0.66 |
Retained Earnings | -1,135 | -1,066 | -754.61 | -530.75 | -383.79 | -228.98 |
Shareholders' Equity | 1,540 | 1,580 | 835.62 | 394.97 | 490.15 | 459.64 |
Total Liabilities & Equity | 1,669 | 1,743 | 978.04 | 575.76 | 603.13 | 605.91 |
Total Debt | 80.47 | 82.25 | 87.76 | 84.67 | 17.34 | 17.96 |
Net Cash (Debt) | 570.46 | 766.02 | 400.98 | 290.21 | 389.83 | 424.46 |
Net Cash Growth | -25.53% | 91.04% | 38.17% | -25.56% | -8.16% | 52.57% |
Net Cash Per Share | 6.42 | 9.07 | 5.34 | 4.97 | 7.23 | 8.85 |
Book Value | 1,540 | 1,580 | 835.62 | 394.97 | 490.15 | 459.64 |
Book Value Per Share | 17.34 | 18.70 | 11.14 | 6.77 | 9.09 | 9.58 |
Tangible Book Value | 1,540 | 1,580 | 835.62 | 394.97 | 490.15 | 459.64 |
Tangible Book Value Per Share | 17.34 | 18.70 | 11.14 | 6.77 | 9.09 | 9.58 |